Dengue tetravalent vaccine - Takeda
Alternative Names: DEN1-DEN2-DEN3-DEN4 vaccine - Takeda; Dengue tetravalent vaccine (live, attenuated) - Takeda; Dengue vaccine tetravalent - Takeda; DENVax™; Needle-free dengue vaccine; QDENGA; Qdenga; TAK-003; TDV - Takeda; Tetravalent dengue vaccine - TakedaLatest Information Update: 06 Sep 2024
At a glance
- Originator Centers for Disease Control and Prevention; Inviragen
- Developer PharmaJet; Takeda
- Class Attenuated vaccines; Dengue vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dengue
Most Recent Events
- 30 Aug 2024 Takeda plans a phase III trial for Dengue (Prevention, In adults, In the elderly) in March 2025 (SC) (NCT06579755)
- 31 May 2024 Registered for Dengue (Prevention) in Israel (SC), before May 2024 (Takeda pipeline, August 2024)
- 31 May 2024 Registered for Dengue (Prevention) in Vietnam (SC), before May 2024 (Takeda pipeline, August 2024)